Design of antiretroviral drug interaction studies

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 313-318

  Kakuda, Thomas N ^a   Schöller Gyüre, Monika ^b  

^a Tibotec Inc   (United States)

^b TIBOTEC BVBA   (Belgium)

Author keywords

Antiretrovirals; Drug drug interaction; HIV; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; APLAVIROC; ENFUVIRTIDE; LOPINAVIR; REPAGLINIDE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VORICONAZOLE;

DRUG POTENTIATION; PRIORITY JOURNAL; REVIEW;

EID: 42049115898     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f7cd90     Document Type: Review

References (34)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, District of Columbia, USA: US Department of Health and Human Services; 2008. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 27 February 2008].
2. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med 2006; 7:487-503.
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
4. Pau AK. Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS 2008.
5. Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81:298-304. This paper is a comprehensive summary of the draft US Food and Drug Administration Guidance for Industry document on the design and analysis of drug interactions.
6. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43:443-469.
7. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31:815-832.
8. Reed JF. Analysis of two-treatment, two-period crossover trials in emergency medicine. Ann Emerg Med 2004; 43:54-58.
9. Fuhr U, Jetter A, Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. Clin Pharmacol Ther 2007; 81:270-283. This paper is an excellent review of acceptable probes and cocktails for assessing the inhibition or induction potential of a compound.
10. Chainuvati S, Nafziger AN, Leeder JS, et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase- 2, and xanthine oxidase activities with the 'Cooperstown 5+1 cocktail'. Clin Pharmacol Ther 2003; 74:437-447.
11. Johnson BM, Song IH, Adkison KK, et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail. J Clin Pharmacol 2006; 46:577-587.
12. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42:52-60. This is an excellent paper describing the use of a modified Cooperstown 5 + 1 cocktail to elucidate the effects of lopinavir/ritonavir on phase I metabolizing enzymes.
13. Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir (TPV/r) on the activity of hepatic and intestinal cytochrome P450 3A4/5 and P-glycoprotein (P-gp): implications for drug interactions. In: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, USA. Alexandria, Virginia, USA: CROI; 2007. http://www.retroconference.org/2007/PDFs/ 563.pdf [Accessed 27 February 2008]. [Accessed 11 February 2007].
14. Zhou H. Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? J Clin Pharmacol 2006; 46:1268-1289. This paper is a comprehensive review of assessing drug-drug interactions using population pharmacokinetics.
15. Gonzalez de Requena D, Calcagno A, Bonora S, et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 2006; 20:1977-1979.
16. Raffi F, Battegay M, Rusconi S, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007; 21:1977-1980.
17. Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-186.
18. Pledger G. The role of a placebo-treated control group in combination drug trials. Control Clin Trials 1989; 10:97-107.
19. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196(Suppl 1):S63-S75.
20. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions: review of the literature. Eur J Med Res 2007; 12:409-417.
21. Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006; 80:126-135.
22. Liu P, Foster G, Gandelman K, et al. Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51:3617-3626.
23. Bidstrup TB, Stilling N, Damkier P, et al. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur J Clin Pharmacol 2004; 60:109-114.
24. Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42:819-850.
25. Culm-Merdek KE, von Moltke LL, Gan L, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 2006; 79:243-254.
26. Purkins L, Love ER, Eve MD, et al. The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unit. Br J Clin Pharmacol 2004; 57:199-208.
27. Gordin FM, Cohn DL, Matts JP, et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 2004; 39:561-565.
28. la Porte CJ, Colbers EP, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48:1553-1560.
29. Grange S, Schutz M, Schmitt C, Riek M, Gaudeul-Ehrhart E. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted saquinavir and vice versa [abstract 35]. In: Program and Abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; 28-30 April 2005; Quebec City, Canada. Education BV: Utrecht, The Netherlands; 2005.
30. Dickenson L, Khoo S, Back D: Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons. Curr Opin HIV AIDS 2008.
31. Slain D, Pakyz A, Israel DS, et al. Variability in activity of hepatic CYP3A4 in patients infected with HIV. Pharmacotherapy 2000; 20:898-907.
32. Lee LS, Nafziger AN, Bertino JS Jr. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005; 78:1-6.
33. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15:657-680.
34. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28:72-78.